tiprankstipranks
Telix Pharmaceuticals Ltd. (AU:TLX)
OTHER OTC:TLX
Australian Market
TLX
Telix Pharmaceuticals
RESEARCH TOOLSreports
Want to see AU:TLX full AI Analyst Report?

Telix Pharmaceuticals (TLX) Share Forecast & Price Target

610 Followers
See the Price Targets and Ratings of:

TLX Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Telix
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TLX Stock 12 Month Forecast

Average Price Target

AU$25.20
▲(72.13% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is AU$25.20 with a high forecast of AU$32.00 and a low forecast of AU$18.00. The average price target represents a 72.13% change from the last price of AU$14.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"AU$8","33":"AU$33","14.25":"AU$14.25","20.5":"AU$20.5","26.75":"AU$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$25.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.25,20.5,26.75,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.02,18.17230769230769,19.324615384615385,20.476923076923075,21.62923076923077,22.78153846153846,23.933846153846154,25.086153846153845,26.238461538461536,27.39076923076923,28.543076923076924,29.695384615384615,30.847692307692306,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.02,17.64923076923077,18.27846153846154,18.907692307692308,19.536923076923078,20.166153846153847,20.795384615384616,21.424615384615386,22.053846153846152,22.683076923076925,23.31230769230769,23.94153846153846,24.57076923076923,{"y":25.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.02,17.095384615384614,17.17076923076923,17.246153846153845,17.321538461538463,17.396923076923077,17.47230769230769,17.54769230769231,17.623076923076923,17.698461538461537,17.773846153846154,17.84923076923077,17.924615384615386,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.57,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.02,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetAU$32.00Average Price TargetAU$25.20Lowest Price TargetAU$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on AU:TLX
David Dai
UBS
UBS
AU$31
Buy
111.75%
Upside
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Telix Pharmaceuticals (Other OTC: TLPPF)
Citi Analyst forecast on AU:TLX
Laura Sutcliffe
Citi
Citi
AU$32
Buy
118.58%
Upside
Reiterated
06/30/26
Analysts Conflicted on These Healthcare Names: Pyxis Oncology (NASDAQ: PYXS) and Telix Pharmaceuticals (Other OTC: TLPPF)
Canaccord Genuity Analyst forecast on AU:TLX
Shane Storey
Canaccord Genuity
Canaccord Genuity
AU$30
Buy
104.92%
Upside
Reiterated
05/25/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Telix Pharmaceuticals (Other OTC: TLPPF)
Morgan Stanley Analyst forecast on AU:TLX
David Bailey
Morgan Stanley
Morgan Stanley
AU$22.4
Buy
53.01%
Upside
Reiterated
05/24/26
Analyst Reiterates Buy on Telix Pharmaceuticals, Sees 38–42% Upside with Unchanged $22.4 Price Target
Bell Potter Analyst forecast on AU:TLX
John Hester
Bell Potter
Bell Potter
AU$19
Buy
29.78%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Telix Pharmaceuticals (Other OTC: TLPPF)
Jefferies Analyst forecast on AU:TLX
David Stanton
Jefferies
Jefferies
AU$24.3→AU$27.4
Buy
87.16%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)
RBC Capital Analyst forecast on AU:TLX
Craig Wong-Pan
RBC Capital
RBC Capital
AU$18
Buy
22.95%
Upside
Reiterated
04/15/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Medline (MDLN)
Jarden Analyst forecast on AU:TLX
Steven Wheen
Jarden
Jarden
AU$21→AU$21.8
Buy
48.91%
Upside
Reiterated
04/07/26
Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TD Cowen Analyst forecast on AU:TLX
Tara Bancroft
TD Cowen
TD Cowen
AU$20
Buy
36.61%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on AU:TLX
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
AU$22.6
Buy
54.37%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on AU:TLX
Andrew Paine
CLSA
CLSA
AU$24.25
Buy
65.64%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on AU:TLX
David Dai
UBS
UBS
AU$31
Buy
111.75%
Upside
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Telix Pharmaceuticals (Other OTC: TLPPF)
Citi Analyst forecast on AU:TLX
Laura Sutcliffe
Citi
Citi
AU$32
Buy
118.58%
Upside
Reiterated
06/30/26
Analysts Conflicted on These Healthcare Names: Pyxis Oncology (NASDAQ: PYXS) and Telix Pharmaceuticals (Other OTC: TLPPF)
Canaccord Genuity Analyst forecast on AU:TLX
Shane Storey
Canaccord Genuity
Canaccord Genuity
AU$30
Buy
104.92%
Upside
Reiterated
05/25/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Telix Pharmaceuticals (Other OTC: TLPPF)
Morgan Stanley Analyst forecast on AU:TLX
David Bailey
Morgan Stanley
Morgan Stanley
AU$22.4
Buy
53.01%
Upside
Reiterated
05/24/26
Analyst Reiterates Buy on Telix Pharmaceuticals, Sees 38–42% Upside with Unchanged $22.4 Price Target
Bell Potter Analyst forecast on AU:TLX
John Hester
Bell Potter
Bell Potter
AU$19
Buy
29.78%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Telix Pharmaceuticals (Other OTC: TLPPF)
Jefferies Analyst forecast on AU:TLX
David Stanton
Jefferies
Jefferies
AU$24.3→AU$27.4
Buy
87.16%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)
RBC Capital Analyst forecast on AU:TLX
Craig Wong-Pan
RBC Capital
RBC Capital
AU$18
Buy
22.95%
Upside
Reiterated
04/15/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Medline (MDLN)
Jarden Analyst forecast on AU:TLX
Steven Wheen
Jarden
Jarden
AU$21→AU$21.8
Buy
48.91%
Upside
Reiterated
04/07/26
Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TD Cowen Analyst forecast on AU:TLX
Tara Bancroft
TD Cowen
TD Cowen
AU$20
Buy
36.61%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on AU:TLX
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
AU$22.6
Buy
54.37%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on AU:TLX
Andrew Paine
CLSA
CLSA
AU$24.25
Buy
65.64%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

3 Months
David StantonJefferies
Success Rate
14/18 ratings generated profit
78%
Average Return
+24.54%
Copying David Stanton's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +24.54% per trade.
1 Year
Steven WheenJarden
Success Rate
20/25 ratings generated profit
80%
Average Return
+51.42%
Copying Steven Wheen's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +51.42% per trade.
2 Years
John HesterBell Potter
Success Rate
14/20 ratings generated profit
70%
Average Return
+47.67%
Copying John Hester's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +47.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
31
30
23
14
5
Buy
1
5
6
6
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
35
29
20
7
In the current month, TLX has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TLX average Analyst price target in the past 3 months is 25.20.
Each month's total comprises the sum of three months' worth of ratings.

TLX Financial Forecast

TLX Earnings Forecast

Next quarter’s earnings estimate for TLX is AU$0.03 with a range of AU$0.03 to AU$0.03. The previous quarter’s EPS was -AU$0.02. TLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.
Next quarter’s earnings estimate for TLX is AU$0.03 with a range of AU$0.03 to AU$0.03. The previous quarter’s EPS was -AU$0.02. TLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.

TLX Sales Forecast

Next quarter’s sales forecast for TLX is AU$340.73M with a range of AU$336.30M to AU$343.52M. The previous quarter’s sales results were AU$630.94M. TLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.
Next quarter’s sales forecast for TLX is AU$340.73M with a range of AU$336.30M to AU$343.52M. The previous quarter’s sales results were AU$630.94M. TLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.

TLX Stock Forecast FAQ

What is AU:TLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 25.20.
    What is AU:TLX’s upside potential, based on the analysts’ average price target?
    Telix Pharmaceuticals Ltd. has 72.13% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?
          Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Telix Pharmaceuticals Ltd.’s share price target?
            The average share price target for Telix Pharmaceuticals Ltd. is 25.20. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is AU$32.00 ,and the lowest forecast is AU$18.00. The average share price target represents 72.13% Increase from the current price of AU$14.64.
              What do analysts say about Telix Pharmaceuticals Ltd.?
              Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Telix Pharmaceuticals Ltd.?
                To buy shares of AU:TLX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.